Yan-Nan Zang1,2, Wei Guo1,2, Meng-Xi Niu1,2, Shuang Bao1,2, Qian Wang1,2, Yan Wang1,2, Fang Dong1,2, An-Ning Li1,2, Can-Jun Ruan3,4. 1. The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China. 2. Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China. 3. The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China. rcjjenny@ccmu.edu.cn. 4. Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China. rcjjenny@ccmu.edu.cn.
Abstract
PURPOSE: To develop and validate a population pharmacokinetic (PPK) model of valproic acid (VPA) in adult Chinese patients with bipolar disorder, and provide guidance for individualized therapy in this population. METHODS: A total of 1104 serum concentrations from 272 patients were collected in this study. The data analysis was performed using a nonlinear mixed-effects modeling approach. Covariates included demographic parameters, biological characteristics, and concomitant medications. Bootstrap validation (1000 runs), normalized prediction distribution error (NPDE), and external validation of 50 patients were employed to evaluate the final model. RESULTS: A one-compartment model with first-order absorption and elimination was developed for VPA extended-release tablets. VPA clearance was significantly influenced by three variables: sex (12% higher in male patients), daily dose (increasing with the 0.13 exponent), and body weight (increasing with the 0.56 exponent). Typical values for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) for a female patient weighing 70 kg administered VPA 1000 mg/day were 0.18 h-1, 0.46 L/h, and 12.84 L, respectively. The results of model evaluation indicated a good stable and precise performance of the final model. CONCLUSIONS: A qualified PPK model of VPA was developed in Chinese patients with bipolar disorder. This model could be used as a suitable tool for the personalization of VPA dosing for bipolar patients.
PURPOSE: To develop and validate a population pharmacokinetic (PPK) model of valproic acid (VPA) in adult Chinese patients with bipolar disorder, and provide guidance for individualized therapy in this population. METHODS: A total of 1104 serum concentrations from 272 patients were collected in this study. The data analysis was performed using a nonlinear mixed-effects modeling approach. Covariates included demographic parameters, biological characteristics, and concomitant medications. Bootstrap validation (1000 runs), normalized prediction distribution error (NPDE), and external validation of 50 patients were employed to evaluate the final model. RESULTS: A one-compartment model with first-order absorption and elimination was developed for VPA extended-release tablets. VPA clearance was significantly influenced by three variables: sex (12% higher in male patients), daily dose (increasing with the 0.13 exponent), and body weight (increasing with the 0.56 exponent). Typical values for the absorption rate constant (Ka), apparent clearance (CL/F), and apparent distribution volume (V/F) for a female patient weighing 70 kg administered VPA 1000 mg/day were 0.18 h-1, 0.46 L/h, and 12.84 L, respectively. The results of model evaluation indicated a good stable and precise performance of the final model. CONCLUSIONS: A qualified PPK model of VPA was developed in Chinese patients with bipolar disorder. This model could be used as a suitable tool for the personalization of VPA dosing for bipolar patients.
Authors: C Hiemke; N Bergemann; H W Clement; A Conca; J Deckert; K Domschke; G Eckermann; K Egberts; M Gerlach; C Greiner; G Gründer; E Haen; U Havemann-Reinecke; G Hefner; R Helmer; G Janssen; E Jaquenoud; G Laux; T Messer; R Mössner; M J Müller; M Paulzen; B Pfuhlmann; P Riederer; A Saria; B Schoppek; G Schoretsanitis; M Schwarz; M Silva Gracia; B Stegmann; W Steimer; J C Stingl; M Uhr; S Ulrich; S Unterecker; R Waschgler; G Zernig; G Zurek; P Baumann Journal: Pharmacopsychiatry Date: 2017-09-14 Impact factor: 5.788
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk Journal: Bipolar Disord Date: 2018-03-14 Impact factor: 6.744
Authors: Kathleen R Merikangas; Robert Jin; Jian-Ping He; Ronald C Kessler; Sing Lee; Nancy A Sampson; Maria Carmen Viana; Laura Helena Andrade; Chiyi Hu; Elie G Karam; Maria Ladea; Maria Elena Medina-Mora; Yutaka Ono; Jose Posada-Villa; Rajesh Sagar; J Elisabeth Wells; Zahari Zarkov Journal: Arch Gen Psychiatry Date: 2011-03
Authors: Michael H Allen; Robert M Hirschfeld; Patricia J Wozniak; Jeffrey D Baker; Charles L Bowden Journal: Am J Psychiatry Date: 2006-02 Impact factor: 18.112
Authors: Roger S McIntyre; Michael Berk; Elisa Brietzke; Benjamin I Goldstein; Carlos López-Jaramillo; Lars Vedel Kessing; Gin S Malhi; Andrew A Nierenberg; Joshua D Rosenblat; Amna Majeed; Eduard Vieta; Maj Vinberg; Allan H Young; Rodrigo B Mansur Journal: Lancet Date: 2020-12-05 Impact factor: 79.321
Authors: C Louwrens Braal; Agnes Jager; Esther Oomen-de Hoop; Justin D Westenberg; Koen M W T Lommen; Peter de Bruijn; Mijntje B Vastbinder; Quirine C van Rossum-Schornagel; Martine F Thijs-Visser; Robbert J van Alphen; Liesbeth E M Struik; Hanneke J M Zuetenhorst; Ron H J Mathijssen; Stijn L W Koolen Journal: Clin Pharmacokinet Date: 2021-11-17 Impact factor: 6.447